Dr. Smagin is a Director of Pharmacology at Melior. He specializes in working with clients to custom-design experiments to evaluate therapeutic efficacy in models of anxiety, depression, sleep/wake (qEEG), and EEG-based seizure activity. He has a broad background and experience in functional neuroanatomy and neurochemistry as well as translational biomarkers for target-based pharmacology and safety assessments. Dr. Smagin is proficient in working with and managing external collaborators, contract research organizations and non-profit organizations.
Prior to joining Melior, he worked at Lundbeck Research USA and AstraZeneca Pharmaceuticals (CNS/Psychiatry discovery) for >15 years where he designed and supervised neurochemical and pharmacological studies involving numerous disease areas, including evaluation of depression, anxiety, Parkinson’s (PD) and Alzheimer’s (AD) diseases and neurodegeneration.
Dr. Smagin received his medical training (MD) from the Siberian Medical University (USSR) and a Ph.D. from the Pavlov Institute of Experimental Medicine (St.Petersburg, Russia). He studied the neurochemistry and neuroendocrinology and neuroimmunology of stress-related disorders. As a postdoctoral fellow and then faculty member at LSU Medical Center in Shreveport, he studied neuroendocrinology of stress and its role in obesity, food intake and addiction.
Dr. Smagin authored and co-authored over 40 peer-reviewed publications in various areas of neuropharmacology and neuropsychiatry including neurodegenerative diseases, AD, depression, anxiety and schizophrenia. Dr. Smagin has regulatory and compliance knowledge, including membership on the Institutional Animal Care and Use committee.